Cholesterol-Lowering Supplement – Cholestifin May Help People Suffering From High Blood Pressure

Press Release (ePRNews.com) - UNIONDALE, N.Y. - Sep 15, 2017 - Cholestifin is a new supplement intended to control cholesterol levels. Bad cholesterol is one of the most dangerous elements in cardiovascular and cerebrovascular diseases and its treatment through drugs is mandatory. People with high cholesterol should first of all change their lifestyle and diet, and then take medicines for treating this so dangerous condition.

The most common cholesterol lowering drugs are statins, and these are usually the first type of medicine that doctors prescribe to lower LDL. These drugs also lower triglycerides – another type of blood fat, which high levels are also dangerous for human’s health. Cholestifin can not be ranked to the group of statins, but it can be used for treating bad cholesterol separately, or as addition to the main treatment.

Beta-glucan, Hawthorn, Omega-3 and L-carnitine are the active ingredients in product’s formula. These are meant to remove cholesterol deposits and normalize lipid values in the blood plasma. Thereby rhvn Cholestifin protects from cardiovascular diseases and minimizes the risk of coronary heart disease. As high cholesterol is one of the main reasons for high blood pressure, treating it normalizes the blood pressure, restores blood circulation and protects the blood vessels.

Looking For Something ?

Search for:

About ePRNews

ePRNews is an established Media Outlet for PR News Submission and digital distribution. We allow business to setup their own Press and News Media room to highlight their Press Release, News, Events, Service Announcements in most flexible and easiest way.

Register New Account

Reset Password

DISCLAIMER

If you have any concerns regarding this press release, please contact the Author / Media Contact / Business of this press release. ePRNews is not resposible for the accuracy of the news posted and do not endorse, support any product/ services/ business mentioned and hereby disclaims any content contained in this press release.